Yubo International Biotech Limited
YBGJ
$0.01
-$0.01-37.09%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 12.40K | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 12.40K | -- | -- | -- | 0.00 |
| Cost of Revenue | 4.20K | -- | -- | -- | -4.30K |
| Gross Profit | 8.20K | -- | -- | -- | 4.30K |
| SG&A Expenses | 154.00K | 239.80K | 233.60K | 380.40K | 284.40K |
| Depreciation & Amortization | 44.40K | 43.60K | 45.10K | 44.60K | 42.40K |
| Other Operating Expenses | 95.20K | 26.80K | -29.00K | 42.30K | 30.50K |
| Total Operating Expenses | 297.80K | 310.10K | 249.70K | 467.30K | 353.00K |
| Operating Income | -285.50K | -310.10K | -249.70K | -467.30K | -353.00K |
| Income Before Tax | -285.70K | -310.20K | -249.70K | -467.30K | -352.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -285.70K | -310.20K | -249.70K | -467.30K | -352.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 24.20K | 33.40K | 19.40K | 31.70K | 63.20K |
| Net Income | -261.40K | -276.80K | -230.30K | -435.60K | -289.70K |
| EBIT | -285.50K | -310.10K | -249.70K | -467.30K | -353.00K |
| EBITDA | -241.00K | -266.50K | -204.60K | -422.70K | -310.60K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 170.76M | 147.87M | 119.82M | 119.82M | 119.82M |
| Average Diluted Shares Outstanding | 170.76M | 147.87M | 119.82M | 119.82M | 119.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |